| [1] |
Mazzaferro V, Chun YS, Poon RT, et al. Liver transplantation for hepatocellular carcinoma[J]. Ann Surg Oncol,2008,15(4):1001-1007. doi: 10.1245/s10434-007-9559-5
|
| [2] |
Byam J, Renz J, Millis JM. Liver transplantation for hepatocellular carcinoma[J]. Hepatobiliary Surg Nutr,2013,2(1):22-30.
|
| [3] |
王征,周俭.肝癌肝移植术后的综合治疗[J].中华肝脏病杂志,2013,21(5):324-325. http://d.wanfangdata.com.cn/Periodical/zhgzbzz201305002
Wang Z, Zhou J. Combined modality therapy for recurrent hepatocellular carcinoma following liver transplantation[J]. Chin J Hepatol,2013,21(5):324-325. http://d.wanfangdata.com.cn/Periodical/zhgzbzz201305002
|
| [4] |
中国肝移植注册.1980-2010年中国肝移植总体情况[J/CD].中华移植杂志:电子版,2011,5(4):267-269.
China liver transplant registry. Overall situation of liver transplantation in China from 1980 to 2010[J/CD].Chin J Transplant: Electronic Version, 2011,5(4):267-269.
|
| [5] |
徐骁,杨家印,钟林,等.肝癌肝移植"杭州标准"的多中心应用研究——1163例报道[J].中华器官移植杂志,2013,34(9):524-527. http://d.wanfangdata.com.cn/Periodical/zhqgyz98201309004
Xu X, Yang JY, Zhong L, et al. The clinical value of "Hangzhou Criteria" in the selection of patients with hepatocellular carcinoma for liver transplantation: a report of 1163 cases on a multi-center basis[J]. Chin J Organ Transplant,2013,34(9):524-527. http://d.wanfangdata.com.cn/Periodical/zhqgyz98201309004
|
| [6] |
Guiteau JJ, Cotton RT, Washburn WK, et al. An early regional experience with expansion of Milan criteria for liver transplant recipients[J]. Am J Transplant,2010,10(9):2092-2098. doi: 10.1111/j.1600-6143.2010.03222.x
|
| [7] |
吕允凤,封宇飞,胡欣,等.索拉非尼的药理及临床研究[J].中国新药杂志,2007,16(1):88-91. http://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ200701026.htm
Lyu YF, Feng YF, Hu X, et al. Sorafenib: pharmacology and clinical studies[J]. Chin J New Drugs,2007,16(1):88-91. http://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ200701026.htm
|
| [8] |
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med,2008,359(4):378-390. doi: 10.1056/NEJMoa0708857
|
| [9] |
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol,2009,10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7
|
| [10] |
Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature[J]. Crit Rev Oncol Hematol, 2014, DOI: 10.1016/j.critrevonc.2013.12.013[Epub ahead of print].
|
| [11] |
Chow PK, Poon DY, Khin MW, et al. Multicenter phase Ⅱ study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma[J]. PLoS One,2014,9(3):e90909. doi: 10.1371/journal.pone.0090909
|
| [12] |
陈路锋,苏洪英,徐克,等. 索拉非尼联合经肝动脉化疗栓塞术治疗原发性肝细胞癌的疗效和安全性[J]. 中国医学科学院学报,2014,36(1):33-36. http://www.cnki.com.cn/Article/CJFDTOTAL-ZYKX201401006.htm
Chen LF, Su HY, Xu K, et al. Efficacy and safety of combination of sorafenib and transarterial chemoembolization in treating primary hepatocellular carcinoma[J]. Acta Acad Med Sin,2014,36(1):33-36. http://www.cnki.com.cn/Article/CJFDTOTAL-ZYKX201401006.htm
|
| [13] |
Frenette CT, Boktour M, Burroughs SG, et al. Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation[J]. Transpl Int,2013,26(7):734-739. doi: 10.1111/tri.2013.26.issue-7
|
| [14] |
Vitale A, Volk ML, Pastorelli D, et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety[J]. Hepatology,2010,51(1):165-173. doi: 10.1002/hep.23260
|
| [15] |
Yoo EJ, Shin HS, Kim SU, et al. Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma[J]. Onco Targets Ther,2013,6:755-759. http://cn.bing.com/academic/profile?id=1700204970&encoded=0&v=paper_preview&mkt=zh-cn
|
| [16] |
Adair A, Wigmore SJ. Sorafenib for hepatocellular carcinoma before liver transplantation[J]. Transpl Int,2013,26(11):e100-e101. doi: 10.1111/tri.2013.26.issue-11
|
| [17] |
Truesdale AE, Caldwell SH, Shah NL, et al. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant[J]. Transpl Int,2011,24(10):991-998. doi: 10.1111/tri.2011.24.issue-10
|
| [18] |
Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis[J]. Lancet Oncol,2009,10(1):35-43. doi: 10.1016/S1470-2045(08)70284-5
|
| [19] |
Roh YN, David Kwon CH, Song S, et al. The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation[J]. Clin Transplant,2014,28(1):141-148. doi: 10.1111/ctr.12286
|
| [20] |
Zhang Q, Chen H, Li Q, et al. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study[J]. Invest New Drugs,2011,29(6):1360-1369. doi: 10.1007/s10637-011-9726-1
|
| [21] |
Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update[J]. Hepatol Res,2013,43(2):147-154. doi: 10.1111/hepr.2013.43.issue-2
|
| [22] |
陈建斌,陈国勇,孙建军,等.索拉非尼治疗肝癌肝移植术后肿瘤复发的临床疗效观察[J].器官移植,2013,4(2):98-101. http://www.organtranspl.com/browse/detail/qkid/63/id/311.html
Chen JB, Chen GY, Sun JJ, et al. Clinical curative effect of sorafenib on the treatment of recurrent primary liver cancer after liver transplantation[J]. Organ Transplant,2013,4(2):98-101. http://www.organtranspl.com/browse/detail/qkid/63/id/311.html
|
| [23] |
李湘竑,钟克波,刘延,等.索拉菲尼治疗肝癌肝移植术后肿瘤复发患者的疗效及安全性分析[J].南方医科大学学报,2011,31(9):1608-1610. http://www.cnki.com.cn/Article/CJFDTOTAL-DYJD201109035.htm
Li XH, Zhong KB, Liu Y, et al. Safety and efficacy of sorafenib in treatment of tumor recurrence in liver transplantation recipients[J]. J South Med Univ,2011,31(9):1608-1610. http://www.cnki.com.cn/Article/CJFDTOTAL-DYJD201109035.htm
|
| [24] |
Waghray A, Balci B, El-Gazzaz G, et al. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation[J]. Clin Transplant,2013,27(4):555-561. doi: 10.1111/ctr.12150
|
| [25] |
De Simone P, Crocetti L, Pezzati D, et al. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation[J]. Transplant Proc,2014,46(1):241-244. doi: 10.1016/j.transproceed.2013.10.035
|
| [26] |
Sposito C, Mariani L, Germini A, et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study[J]. J Hepatol,2013,59(1):59-66. doi: 10.1016/j.jhep.2013.02.026
|
| [27] |
Pfeiffenberger J, Koschny R, Hoffmann K, et al. Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation[J]. Langenbecks Arch Surg,2013,398(8):1123-1128. doi: 10.1007/s00423-013-1114-1
|
| [28] |
Toso C, Mentha G, Majno P. Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence[J]. J Hepatol,2013,59(1):3-5. doi: 10.1016/j.jhep.2013.03.029
|
| [29] |
黄磊,朱继业,栗光明,等. 索拉非尼预防超米兰标准肝癌患者肝移植术后复发[J].中华普通外科杂志,2011,26(11):936-939. http://d.wanfangdata.com.cn/Periodical/zhptwk201111016
Huang L, Zhu JY, Li GM, et al. Postoperative use of sorafenib in liver transplantation patients of hepatocellular carcinoma beyond Milan criteria[J]. Chin J Gen Surg,2011,26(11):936-939. http://d.wanfangdata.com.cn/Periodical/zhptwk201111016
|
| [30] |
胡安斌,何晓顺,邰强,等.索拉非尼在预防和治疗肝癌肝移植术后肿瘤复发中的疗效评价[J].中华医学杂志,2012,92(18):1264-1267. http://d.wanfangdata.com.cn/Periodical/zhyx201218012
Hu AB, He XS, Tai Q, et al. Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation[J]. Natl Med J China,2012,92(18):1264-1267. http://d.wanfangdata.com.cn/Periodical/zhyx201218012
|
| [31] |
Jia N, Liou I, Halldorson J, et al. Phase Ⅰ adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation[J]. Anticancer Res,2013,33(6):2797-2800. http://cn.bing.com/academic/profile?id=193012423&encoded=0&v=paper_preview&mkt=zh-cn
|
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad: